# Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

> **NCT02092207** · PHASE2 · COMPLETED · sponsor: **Yungjin Pharm. Co., Ltd.** · enrollment: 147 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** KL7016 900mg
- **DRUG:** KL7016 600mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02092207
- **Lead sponsor:** Yungjin Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092207, "Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02092207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*